Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
Completed · Phase 2
Conditions studied: Chronic Graft-versus-host Disease
In brief
Rituximab is an attractive agent to bring to the upfront treatment of chronic graft-versus-host disease (cGVHD) due to its favorable toxicity profile, its proven efficacy in the treatment of steroid-refractory cGVHD, and its ability to serve as a steroid sparing agent in other autoimmune diseases. The investigators hope to demonstrate that Rituximab has significant activity in cGVHD when utilized early in the course of the process. In addition, the investigators hope to show that the early use of Rituximab may allow for the earlier discontinuation of immunosuppression while obviating the need for long courses of systemic corticosteroids, which should translate into reduced treatment-related morbidity and mortality associated with cGVHD.
Key facts
- Study ID
- NCT01161628
- Run by
- Northside Hospital, Inc.
- People needed
- 25
- Starts
- 2011-04-01
- Expected to finish
- 2015-07-01
- Last updated by the study team
- 2016-04-20
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- First episode of extensive chronic GvHD, without residual or concurrent acute GvHD.
- Age 18 - 75
- Any primary diagnosis requiring treatment by allogeneic HSCT
- Recipient of an allogeneic stem cell transplant (bone marrow, peripheral blood stem cell, or cord blood) from a related or unrelated donor, minimum 80 days ago
- Conditioning regimen: Myeloablative or non-myeloablative
- Patient gives written informed consent
You may not qualify if…
- Creatinine > 2.0 mg/dl
- Uncontrolled, active infection
- Recurrent or progressive malignancy
- Anticipated life expectancy of less than 1 year
- Pregnant or breast feeding
- Contraindications to administration of the study intervention or known inability of the patient to tolerate the study intervention
- Patients with perceived fixed, irreversible defects (pulmonary involvement, contractures, etc.) which would not be expected to improve with the study intervention
- Residual or concurrent acute GVHD
Where it is running
- Northside Hospital — Atlanta, Georgia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.